MSLN and cancer: The combination of the bacterial vaccine CRS-207, an attenuated form of a Listeria monocytogenes vector overexpressing human MSLN, with pemetrexed/cisplatin chemotherapy provided objective disease control in unresectable malignant pleural mesothelioma and induced significant clinical responses, suggesting that tumor vaccines may be potential candidates for cancer therapy [45].